Deploying generative AI language services in the Life Sciences industry requires trust and control. In the rapidly emerging field of AI, drug sponsors and MedTech manufacturers take steps cautiously. Understandably, many are not completely ready to entrust Large Language Models (LLMs) and generative AI language providers with their regulated content.

However, through the total product life cycle of your drugs or devices, AI services for life sciences companies can also:

Bring significant cost-savings
Help solve for regulatory time pressure
Bring language consistency to your product information

Read our eBook to discover how to bridge the trust gap and prepare to safely and effectively begin implementing AI-powered language translations — even for regulated product content. Lionbridge explores how to develop a risk-based language strategy for products with AI and life sciences language solutions.

READ OUR EBOOK

DOWNLOAD

Business Email* : Please enter business email

First Name* :

Last Name* :

Company Name* :

Message* :

By checking the box below, you agree to receive our marketing emails. You will receive information on innovative leadership, best practices and market trends in language services. Sign up to receive Lionbridge emails

To unsubscribe and find out how we process your personal information, consult our Privacy Policy.

AUTHORED BY

Pia Windelov, VP, Life Sciences Strategy and Product Marketing

#regulated_translation_localization
#ai
#generative-ai
#life_sciences
#ebook
#blog_posts

WHAT WE DO

AI

INDUSTRIES

Generative AI Language Services eBook

INDUSTRIES